Supplementary filings set to strengthen Velcade's US position
28 April 2011
Ian Haydock
Please Login to read the full article.
28 April 2011
Ian Haydock
ian.haydock@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- SymBio shifts bendamustine's multiple myeloma focus to second-line use
- Will FDA's nod for Millennium's subQ Velcade be a thorn in Onyx's side?
- New data from three Revlimid studies support expanded myeloma indications
- Black-box warning imposed on Seattle Genetics' new lymphoma drug
COMMENT
Other Informa Comment
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
